Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.21 USD | -2.31% | -0.26% | -10.95% |
Financials (USD)
Sales 2024 * | 264M | Sales 2025 * | 413M | Capitalization | 2.25B |
---|---|---|---|---|---|
Net income 2024 * | -16M | Net income 2025 * | 81M | EV / Sales 2024 * | 7.99 x |
Net cash position 2024 * | 146M | Net cash position 2025 * | 259M | EV / Sales 2025 * | 4.83 x |
P/E ratio 2024 * |
-129
x | P/E ratio 2025 * |
29.6
x | Employees | 264 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.9% |
Latest transcript on TG Therapeutics, Inc.
1 day | -2.31% | ||
1 week | -1.04% | ||
Current month | -11.67% | ||
1 month | +9.35% | ||
3 months | -10.79% | ||
6 months | +72.45% | ||
Current year | -10.95% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Sean Power
DFI | Director of Finance/CFO | 42 | 11-12-28 |
Jenna A. Bosco
IRC | Investor Relations Contact | - | 11-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Laurence Charney
BRD | Director/Board Member | 77 | 12-02-29 |
Kenneth Hoberman
BRD | Director/Board Member | 59 | 14-12-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 15.21 | -2.31% | 2,327,786 |
24-03-27 | 15.57 | +0.84% | 1,454,844 |
24-03-26 | 15.44 | -1.59% | 2,651,466 |
24-03-25 | 15.69 | +1.29% | 1,770,918 |
24-03-22 | 15.49 | +1.57% | 2,044,626 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.95% | 2.25B | |
+9.30% | 45.97B | |
+52.73% | 43.93B | |
+7.15% | 42.34B | |
-8.78% | 28.27B | |
+18.68% | 27.18B | |
-21.92% | 19.44B | |
+14.62% | 13.83B | |
+31.85% | 12.4B | |
+4.47% | 11.45B |